secwatch.observer — SEC 8-K summary
======================================

Issuer:     Prelude Therapeutics Inc (PRLD)
CIK:        0001678660
Form:       8-K
Filed at:   2025-11-04T23:59:59+00:00
Accession:  0000929638-25-004115
Event type: other_material
Sentiment:  neutral
Materiality: 0.80
Item codes: 1.01, 3.02, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Prelude gets $60M from Incyte for JAK2V617F option; pauses SMARCA2; CMO resigns
-------------------------------------------------------------------------------

- Incyte receives exclusive option to acquire Prelude's mutant selective JAK2V617F JH2 inhibitor program for $100M exercise price, plus up to $775M milestones and single-digit royalties.
- Prelude receives $60M in capital: $35M upfront plus $25M equity investment (6.25M shares at $4.00 each).
- Company pauses clinical development of SMARCA2 degrader program to prioritize JAK2V617F and KAT6A degrader programs.
- President and CMO Jane Huang resigns; board member Dr. Victor Sandor steps in to oversee clinical development.
- Cash runway extended into 2027 (potentially 2028 if Incyte exercises option); preliminary cash ~$52M as of Oct 31, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1678660/000092963825004115/0000929638-25-004115-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1678660/000092963825004115/a8k.htm
  HTML page:      https://secwatch.observer/filing/0000929638-25-004115

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer